J&J Reportedly Raises Actelion Bid

Nov 30, 2016

Johnson & Johnson has reportedly raised its takeover offer for Actelion, Europe’s largest biotech firm after nearly two months of informal talks. Various reports state that Actelion wants J&J to become a major shareholder in a new entity, whereas J&J seeks a straightforward takeover.

J&J have allegedly significantly increased its offer from an earlier bid of about $26 billion—or $242 per share— that was rejected by Actelion as too low. Actelion shares jumped the most in more than 16 years on November 25 after Bloomberg reported J&J’s interest. Recent deals pharma include Pfizer’s $14 billion acquisition of Medivation.

Still, J&J are reportedly open to discussing other structures for the deal to win the backing of Actelion’s CEO and co-founder Jean-Paul Clozel. An acquisition would boost J&J's pipeline and diversify its prospects as its arthritis drug Remicade faces stiff competition from Pfizer’s biosimilar

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments